Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares. View ANIK analyst ratings or view top-rated stocks .

What is Anika Therapeutics' stock price target for 2024?

2 equities research analysts have issued 12-month target prices for Anika Therapeutics' shares. Their ANIK share price targets range from $23.00 to $28.00. On average, they anticipate the company's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price. View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts .

How have ANIK shares performed in 2023?

Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 24.1% and is now trading at $22.48. View the best growth stocks for 2023 here .

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 489,100 shares, a drop of 7.5% from the October 31st total of 528,900 shares. Based on an average daily trading volume, of 203,300 shares, the short-interest ratio is presently 2.4 days. Currently, 3.4% of the shares of the stock are sold short. View Anika Therapeutics' Short Interest .

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our ANIK earnings forecast .

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company had revenue of $39.54 million for the quarter, compared to analyst estimates of $36.45 million. Anika Therapeutics had a negative net margin of 15.05% and a negative trailing twelve-month return on equity of 3.32%. During the same period in the prior year, the business earned ($0.45) EPS.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA) , Broadcom (AVGO) , Gilead Sciences (GILD) , Micron Technology (MU) , Skyworks Solutions (SWKS) , Tesla (TSLA) , Advanced Micro Devices (AMD) , CVS Health (CVS) , Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND) .

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Trigran Investments Inc. (15.14%), Acadian Asset Management LLC (2.30%), Ameriprise Financial Inc. (1.67%), Northern Trust Corp (1.00%), Charles Schwab Investment Management Inc. (0.78%) and Capital Management Corp VA (0.58%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III , Michael L Levitz and Raymond J Land . View institutional ownership trends .

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Anika Therapeutics Stock Price, News & Analysis (NASDAQ:ANIK)

$22.48

+0.51 (+2.32%)

(As of 12/7/2023 ET)

Compare

Today's Range: $21.84
▼
$22.59
50-Day Range: $18.47
▼
$22.75
52-Week Range: $16.54
▼
$32.33

Volume: 68,194 shs
Average Volume: 118,644 shs
Market Capitalization: $329.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.50

Anika Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 13.4% Upside
$25.50 Price Target
Short Interest: Healthy
3.44% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.70
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.45) to ($0.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

549th out of 960 stocks

Medical Instruments & Supplies Industry

6th out of 8 stocks

2.3

Analyst's Opinion

Consensus Rating
Anika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.50, Anika Therapeutics has a forecasted upside of 13.4% from its current price of $22.48.
Amount of Analyst Coverage
Anika Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.44% of the float of Anika Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Anika Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Anika Therapeutics has recently decreased by 7.53%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Anika Therapeutics does not currently pay a dividend.
Dividend Growth
Anika Therapeutics does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Anika Therapeutics has received a 50.41% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.
Environmental Sustainability
The Environmental Impact score for Anika Therapeutics is -1.70.

1.1

News and Social Media Coverage

Search Interest
2 people have searched for ANIK on MarketBeat in the last 30 days.
MarketBeat Follows
6 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anika Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.85% of the stock of Anika Therapeutics is held by insiders.
Percentage Held by Institutions
90.79% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Anika Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anika Therapeutics is -13.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anika Therapeutics is -13.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anika Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anika Therapeutics Stock (NASDAQ:ANIK)

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANIK Stock News Headlines

November 29, 2023 | msn.com

First surgeries testing rotator cuff augmentation implant carried out in Florida

November 5, 2023 | finance.yahoo.com

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2023 Earnings Call Transcript

December 8, 2023 | Edge On The Street (Ad)

The Battery Metal Nobody Told You About

According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."

November 4, 2023 | markets.businessinsider.com

Anika Therapeutics Receives Buy Rating Based on Strong Q3 Performance and Positive 2023 Outlook

November 3, 2023 | finance.yahoo.com

Q3 2023 Anika Therapeutics Inc Earnings Call

November 2, 2023 | finance.yahoo.com

Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business

November 1, 2023 | msn.com

Anika Therapeutics Q3 2023 Earnings Preview

October 23, 2023 | finance.yahoo.com

Anika Therapeutics, Inc. (NASDAQ:ANIK) is favoured by institutional owners who hold 66% of the company

December 8, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

October 6, 2023 | finance.yahoo.com

Investors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 52% over the last five years

September 19, 2023 | finance.yahoo.com

Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting

September 16, 2023 | finanznachrichten.de

Anika Therapeutics Inc.: Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2023 | finance.yahoo.com

Down -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)

August 17, 2023 | finance.yahoo.com

Caligan Partners LP Boosts Stake in Anika Therapeutics Inc

August 17, 2023 | marketwatch.com

Anika Rotator-Cuff Treatment May Launch in 1Q Following Final FDA Approval

August 17, 2023 | finance.yahoo.com

Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

August 14, 2023 | msn.com

Barrington Research Upgrades Anika Therapeutics (ANIK)

August 11, 2023 | finance.yahoo.com

Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Intrinsic Value Is Potentially 92% Above Its Share Price

August 10, 2023 | msn.com

Stephens & Co. Maintains Anika Therapeutics (ANIK) Equal-Weight Recommendation

August 9, 2023 | finance.yahoo.com

Q2 2023 Anika Therapeutics Inc Earnings Call

August 9, 2023 | finanznachrichten.de

Anika Therapeutics Inc.: Anika Reports Second Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

Advanced wound care market to grow by USD 4,020.97 million from 2022 to 2027|The increasing volume of surgical procedures drives growth - Technavio

July 12, 2023 | finance.yahoo.com

Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting

May 31, 2023 | msn.com

Stephens & Co. Reiterates Anika Therapeutics (ANIK) Equal-Weight Recommendation

May 30, 2023 | finance.yahoo.com

Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone

May 17, 2023 | marketwatch.com

Hemostatic Agents Market Research | 2023-2030

May 16, 2023 | finance.yahoo.com

Global Osteoarthritis Therapeutics Market to Reach $15.8 Billion by 2030

See More Headlines

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical Instruments & Supplies
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:ANIK
CUSIP: 03525510
CIK: 898437
Web: www.anikatherapeutics.com
Phone: (781) 457-9000
Fax: 781-305-9720
Employees: 345
Year Founded: 1992

Price Target and Rating

Average Stock Price Target: $25.50
High Stock Price Target: $28.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +13.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,860,000.00
Net Margins: -15.05%
Pretax Margin: -17.46%
Return on Equity: -3.32%
Return on Assets: -2.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.59
Quick Ratio: 4.03

Sales & Book Value

Annual Sales: $163.31 million
Price / Sales: 2.02
Cash Flow: $0.50 per share
Price / Cash Flow: 44.59
Book Value: $19.55 per share
Price / Book: 1.15

Miscellaneous

Outstanding Shares: 14,641,000
Free Float: 13,785,000
Market Cap: $329.13 million
Optionable: Optionable
Beta: 0.73

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Cheryl Renee Blanchard Ph.D. (Age 59)
President, CEO & Director
Comp: $1.31M
Mr. Michael L. Levitz (Age 49)
Executive VP, CFO & Treasurer
Comp: $710.6k
Mr. David Colleran J.D. (Age 51)
Executive VP, General Counsel & Corporate Secretary
Comp: $664.54k
Ms. Anne Nunes (Age 54)
Senior VP & COO
Mr. Ian W. McLeod
VP & Chief Accounting Officer
Mr. Mark Namaroff (Age 60)
Executive Director of Investor Relations & Corporate Communications
Mr. James Chase
Senior Vice President of International Sales & Marketing
Mr. Ben Joseph
Vice President of Commercial & Corporate Development
Ms. Lisa Funiciello
Vice President of Human Resources

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ANIK Stock Analysis - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares.
View ANIK analyst ratings or view top-rated stocks.
What is Anika Therapeutics' stock price target for 2024?: 2 equities research analysts have issued 12-month target prices for Anika Therapeutics' shares. Their ANIK share price targets range from $23.00 to $28.00. On average, they anticipate the company's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.
How have ANIK shares performed in 2023?: Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 24.1% and is now trading at $22.48.
View the best growth stocks for 2023 here.
Are investors shorting Anika Therapeutics?: Anika Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 489,100 shares, a drop of 7.5% from the October 31st total of 528,900 shares. Based on an average daily trading volume, of 203,300 shares, the short-interest ratio is presently 2.4 days. Currently, 3.4% of the shares of the stock are sold short.
View Anika Therapeutics' Short Interest.
When is Anika Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ANIK earnings forecast.

How were Anika Therapeutics' earnings last quarter?: Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company had revenue of $39.54 million for the quarter, compared to analyst estimates of $36.45 million. Anika Therapeutics had a negative net margin of 15.05% and a negative trailing twelve-month return on equity of 3.32%. During the same period in the prior year, the business earned ($0.45) EPS.
What other stocks do shareholders of Anika Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).
Who are Anika Therapeutics' major shareholders?: Anika Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Trigran Investments Inc. (15.14%), Acadian Asset Management LLC (2.30%), Ameriprise Financial Inc. (1.67%), Northern Trust Corp (1.00%), Charles Schwab Investment Management Inc. (0.78%) and Capital Management Corp VA (0.58%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends.
How do I buy shares of Anika Therapeutics?: Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ANIK) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial